Products Categories
CAS No.: | 51762-05-1 |
---|---|
Name: | Cefroxadine |
Article Data: | 3 |
Molecular Structure: | |
Formula: | C16H19 N3 O5 S |
Molecular Weight: | 365.41 |
Synonyms: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)amino]-3-methoxy-8-oxo-, [6R-[6a,7b(R*)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methoxy-8-oxo-, (6R,7R)-(9CI); CGP 9000; Cefroxadine; Oraspor |
EINECS: | 257-391-8 |
Density: | 1.5 g/cm3 |
Melting Point: | 170° (dec) |
Boiling Point: | 719.3 °C at 760 mmHg |
Flash Point: | 388.8 °C |
Safety: | Mildly toxic by ingestion and intraperitoneal routes. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits toxic fumes of SOx and NOx. |
PSA: | 147.26000 |
LogP: | 0.96170 |
Chemistry informtion about Cefroxadin (CAS NO.51762-05-1) is:
IUPAC Name: (6r,7r)-7-[[(2r)-2-Amino-2-Cyclohexa-1,4-Dien-1-Ylacetyl]Amino]-3-Methoxy-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid ; (6S,7S)-7-[(2-amino-2-cyclohexa-2,5-dien-1-ylacetyl)amino]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Synonyms: (6r-(6-Alpha,7-Beta(R*)))-Ien-1-Ylacetyl)Amino)-3-Methoxy-8-Oxo ; 7-(D-2-Amino-2-(1,4-Cyclohexadienyl)Acetamide)-3-Methoxy-3-Cephem-4-Carboxyl ; Antibioticcgp9000 ; Cefroxadin ; Cgp9000 ; Cxd ; Cefroxadine ; 5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid, 7-[(Amino-1,4-Cyclohexadien-1-Ylacetyl)Amino]-3-Methoxy-8-Oxo-, [6r-[6α,7β(R*)]]-
MF: C16H19N3O5S
MW: 365.4
EINECS: 257-391-8
Density: 1.5 g/cm3
Flash Point: 388.8 °C
Boiling Point: 719.3 °C at 760 mmHg
Vapour Pressure: 1.23E-22 mmHg at 25°C
Enthalpy of Vaporization: 114.44 kJ/mol
Following is the molecular structure of Cefroxadin (CAS NO.51762-05-1) is:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | > 1gm/kg (1000mg/kg) | Drugs in Japan Vol. -, Pg. 689, 1995. | |
mouse | LD50 | intraperitoneal | 7090mg/kg (7090mg/kg) | Journal of Antibiotics. Vol. 29, Pg. 653, 1976. | |
mouse | LD50 | oral | > 13500mg/kg (13500mg/kg) | behavioral: somnolence (general depressed activity) gastrointestinal: "hypermotility, diarrhea" | Chemotherapy Vol. 28(Suppl, |
mouse | LD50 | subcutaneous | 13500mg/kg (13500mg/kg) | behavioral: somnolence (general depressed activity) gastrointestinal: "hypermotility, diarrhea" | Chemotherapy Vol. 28(Suppl, |
rabbit | LD50 | intraperitoneal | > 4gm/kg (4000mg/kg) | kidney, ureter, and bladder: structural or functional changes in ureter kidney, ureter, and bladder: other changes | Chemotherapy Vol. 28(Suppl, |
rabbit | LD50 | oral | 10gm/kg (10000mg/kg) | Drugs in Japan Vol. 6, Pg. APP-11, 1982. | |
rat | LD50 | intraperitoneal | 6gm/kg (6000mg/kg) | behavioral: ataxia gastrointestinal: "hypermotility, diarrhea" skin and appendages (skin): hair: other | Chemotherapy Vol. 28(Suppl, |
rat | LD50 | oral | > 22500mg/kg (22500mg/kg) | behavioral: altered sleep time (including change in righting reflex) behavioral: somnolence (general depressed activity) gastrointestinal: "hypermotility, diarrhea" | Chemotherapy Vol. 28(Suppl, |
rat | LD50 | subcutaneous | > 15gm/kg (15000mg/kg) | sense organs and special senses: mydriasis (pupillary dilation): eye behavioral: altered sleep time (including change in righting reflex) skin and appendages (skin): hair: other | Chemotherapy Vol. 28(Suppl, |
Mildly toxic by ingestion and intraperitoneal routes. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits toxic fumes of SOx and NOx.